Posts

Showing posts from November, 2022

The impact of physical properties of API on pre-prescription studies of injectables

Image
People may take medicine when they catch a cold daily; some take tablets, and some take capsules; these tablets and capsules are pharmaceutical preparations. Pre-prescription study of drug formulation is the understanding, analysis, utilization, or improvement of a series of fundamental physical, chemical, and formulation properties of a drug before designing a formulation prescription to make the drug stable, effective, and in line with the requirements of formulation prescription and formulation process in industrial production. Medicilon can provide professional pre-prescribing services and uncover valuable information to lead the compound into late-stage development for tiny quantities of active pharmaceutical ingredients or candidate compounds with drug-forming properties. The impact of physical properties of active pharmaceutical ingredients (APIs) on pre-prescription studies of injectables is one of the main points of pre-prescription studies of injectables, which are mainly re

What are the business models of pharmaceutical R&D outsourcing organizations?

 Pharmaceutical R&D outsourcing CRO refers to pharmaceutical companies using the purchase of new drug clinical or preclinical research and other services from a third party, and the contractor is responsible for the work tasks of drug development trials and declaration of registration within the scope of the contract, mainly serving the stage of new drug launch and before.  The pressure of new drug R&D has led to the rise of new drug R&D outsourcing services and has also driven the global CRO industry to take off. Consistency evaluation of generic drugs, self-checking and verification of drug clinical trials, and acceleration of drug trials are driving the domestic CRO market to the 100 billion level. The current high cost of pharmaceutical R&D, the reduced success rate of R&D, and massive patent expiration have prompted pharmaceutical companies to be more eager to improve the efficiency and speed of R&D, which has accelerated the development of the specializ

Does Metformin, a glucose-lowering drug, hurt the kidneys?

Image
  Metformin is a biguanide compound that reduces blood sugar mainly by reducing hepatic glucose output, improving insulin resistance, and reducing glucose absorption in the small intestine. It is currently one of the world's most widely used oral hypoglycemic drugs. Drug safety evaluation studies have found that Metformin has a good safety profile, no carcinogenic or mutagenic effects, and no evidence that Metformin can increase the risk of lactic acidosis. Medicilon has a professional team and experience in preclinical drug safety evaluation services, providing high-quality data and a fast turnaround time to support all drug safety evaluation studies. Many patients are concerned about the effects of long-term metformin use on the kidneys. The drug does not directly damage the kidneys but can lead to drug accumulation when taken by patients with existing kidney damage. Both the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes (2017 edition) and the Expert C